48 Result(s)
within
Kevin J. Harrington
-
Article
Open AccessAntitumour effect of the mitochondrial complex III inhibitor Atovaquone in combination with anti-PD-L1 therapy in mouse cancer models
Immune checkpoint blockade (ICB) provides effective and durable responses for several tumour types by unleashing an immune response directed against cancer cells. However, a substantial number of patients trea...
-
Chapter and Conference Paper
DNA Repair Mechanisms as a New Target in Head and Neck Cancer
Until recently, radiotherapy was viewed solely from a tumour cell-autonomous perspective, whereby successful therapy resulted from inflicting breaks in nuclear DNA above an unspecified threshold that exceeded ...
-
Article
Open AccessCorrection: Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy
-
Article
Open AccessTriggering anti-GBM immune response with EGFR-mediated photoimmunotherapy
Surgical resection followed by chemo-radiation postpones glioblastoma (GBM) progression and extends patient survival, but these tumours eventually recur. Multimodal treatment plans combining intraoperative tec...
-
Article
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma
How targeted therapies and immunotherapies shape tumors, and thereby influence subsequent therapeutic responses, is poorly understood. In the present study, we show, in melanoma patients and mouse models, that...
-
Article
Open AccessTP53 modulates radiotherapy fraction size sensitivity in normal and malignant cells
Recent clinical trials in breast and prostate cancer have established that fewer, larger daily doses (fractions) of radiotherapy are safe and effective, but these do not represent personalised dosing on a pati...
-
Chapter and Conference Paper
Is there a Role for Adjuvant Targeted and Immunotherapies in Patients with Locoregionally-Advanced Head and Neck Cancer?
Despite significant technical improvements in the management of patients with locoregionally-advanced head and neck cancers, too many patients fail to achieve durable remissions that ultimately translate into ...
-
Article
Open AccessImmunomodulatory activity of IR700-labelled affibody targeting HER2
There is an urgent need to develop therapeutic approaches that can increase the response rate to immuno-oncology agents. Photoimmunotherapy has recently been shown to generate anti-tumour immunological respons...
-
Article
Author Correction: STING and IRF3 in stromal fibroblasts enable sensing of genomic stress in cancer cells to undermine oncolytic viral therapy
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
-
Article
STING and IRF3 in stromal fibroblasts enable sensing of genomic stress in cancer cells to undermine oncolytic viral therapy
Cancer-associated fibroblasts (CAFs) perform diverse roles and can modulate therapy responses1. The inflammatory environment within tumours also influences responses to many therapies, including the efficacy of o...
-
Article
Inflammatory microenvironment remodelling by tumour cells after radiotherapy
The development of immune checkpoint inhibitors (ICIs) is revolutionizing the way we think about cancer treatment. Even so, for most types of cancer, only a minority of patients currently benefit from ICI ther...
-
Article
Immunological impact of cell death signaling driven by radiation on the tumor microenvironment
Therapeutic irradiation of the tumor microenvironment causes differential activation of pro-survival and pro-death pathways in malignant, stromal, endothelial and immune cells, hence causing a profound cellula...
-
Article
Open AccessDevelopment of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1
Oncolytic viruses preferentially replicate in tumors as compared to normal tissue and promote immunogenic cell death and induction of host systemic anti-tumor immunity. HSV-1 was chosen for further development...
-
Article
Open AccessThe Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and 380,000 deaths worldwide per annum,...
-
Article
Open AccessPlasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21
The oncolytic virus, coxsackievirus A21 (CVA21), has shown promise as a single agent in several clinical trials and is now being tested in combination with immune checkpoint blockade. Combination therapies off...
-
Article
Open AccessFinal analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe, Australia and Switzerland. We report the final planned analysis of OPTiM, a randomized open-label phase III trial in patients ...
-
Article
Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe
Talimogene laherparepvec, a herpes simplex virus type 1-based intrale-sional oncolytic immunotherapy, is approved in Europe for the treatment of adults with unresectable stage IIIB-IVM1a melanoma, with no bone...
-
Article
Open AccessChanges in multimodality functional imaging parameters early during chemoradiation predict treatment response in patients with locally advanced head and neck cancer
To assess the optimal timing and predictive value of early intra-treatment changes in multimodality functional and molecular imaging (FMI) parameters as biomarkers for clinical remission in patients receiving ...
-
Chapter
Homologous Recombination Repair Function as a Predictor of Treatment Response
Homologous recombination repair (HRR) is a normal cellular process by which spontaneous (endogenous) and exogenous DNA damage is corrected and, as such, it is essential to maintenance of normal tissue homeosta...
-
Chapter
Targeting ATR for Cancer Therapy: ATR-Targeted Drug Candidates
ATR inhibitors are a new class of anti-cancer compounds reaching early phase clinical trials. They are predicted to have anti-cancer activity as monotherapy, and in combination with DNA damaging chemotherapies...
